JAGX (JAGX) Stock Analysis
Verdict: AVOID
Extreme liquidity depletion and persistent net losses expose JAGX to imminent dilution risk, driving a -74.14% crash toward its $3.21 target.
Investment score: 10/100
Is JAGX Stock Worth Reviewing? AI Model Thesis
The model views JAGX as an uninvestable microcap due to near-zero cash runway ($0.97M USD), negative equity (-$17.29M USD), and high debt ($43.61M USD). Following a -74.14% single-day crash to $8.91 USD, further dilution appears imminent.
Should You Buy or Sell JAGX Stock? Model Reasoning
Jaguar Health faces existential liquidity stress with only $0.97M USD in cash as of end-2025 against $40.65M USD in current liabilities and TTM net losses of -$53.43M USD. Combined with a single-analyst price target of $3.21 USD and an ongoing history of capital dilution, the AI model sees an unacceptably high probability of further equity impairment.
JAGX Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Operating loss remains severe at -$45.11M against annual sales of $11.51M","Cash position of $0.97M implies less than 1 month of independent operating runway without extreme equity dilution or debt restructuring","Book value is negative at -$17.29M, indicating severe balance sheet deficit"]
JAGX Risk & Opportunity Analysis
Key Investment Risks
- Existential liquidity deficit and imminent share dilution — With cash at $0.97M USD vs current liabilities of $40.65M USD, the firm must execute severe equity dilution or face insolvency within 1 to 3 months.
- Insolvency and capital structure distress — Negative book value of -$17.29M USD and $43.61M USD in total debt leave equity holders exposed to total loss in a potential restructuring event.
- Overvaluation relative to single-analyst target price — Stock trading at $8.91 USD remains 177% above the consensus target of $3.21 USD, exposing holders to further fundamental down-side repricing.
- Exchange delisting and severe illiquidity risk — Failure to meet NASDAQ listing requirements after prior massive reverse splits could lead to over-the-counter (OTC) demotion, destroying trading volume.
Growth Opportunities & Upside Drivers
- FDA expansion trials for crofelemer in cancer therapy-related diarrhea — Successful Phase 3 data or regulatory approval in broader cancer supportive care could significantly scale revenue beyond the $11.51M USD 2025 base by 2027.
- High TTM gross margin of 82.31% — Demonstrates strong underlying unit economics for Mytesi, allowing top-line growth to translate efficiently if operating cash burn is contained.
- Pipeline optionality in rare pediatric diseases and animal health — Orphan drug designations for congenital diarrheal disorders provide potential priority review vouchers or non-dilutive licensing opportunities.
- 135.52% top-line revenue growth in recent trailing periods — Shows commercial demand expansion for core gastrointestinal products, offering a fundamental base if debt restructuring occurs.
JAGX Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About JAGX (JAGX)
Is JAGX stock a good investment?
The cached TradeMates AI model rates JAGX as AVOID with an investment score of 10/100. The model views JAGX as an uninvestable microcap due to near-zero cash runway ($0.97M USD), negative equity (-$17.29M USD), and high debt ($43.61M USD). Following a -74.14% single-day crash to $8.91 USD, further dilution appears imminent. This is algorithmic model output, not personal investment advice.
Does JAGX pay a dividend?
The cached stock data on this page does not show a positive dividend yield for JAGX. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does JAGX stock do?
Commercial-stage specialty pharmaceutical company focused on developing and commercializing plant-derived prescription medicines (crofelemer/Mytesi) for gastrointestinal indications.
What is JAGX stock's price target?
This cached page does not contain a precise model fair value for JAGX.
Is JAGX stock a buy?
The TradeMates model verdict for JAGX is AVOID with an investment score of 10/100. Treat this as a model signal to review, not a personal buy recommendation.
Is JAGX a good dividend stock?
JAGX is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.